| Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? DH Simsek, S Kuyumcu, C Turkmen, Y Sanlı, F Aykan, S Unal, I Adalet Journal of Nuclear Medicine 55 (11), 1811-1817, 2014 | 108 | 2014 |
| The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels Y Sanli, S Kuyumcu, ZG Ozkan, L Kilic, E Balik, C Turkmen, D Has, G Isik, ... Annals of nuclear medicine 26, 551-558, 2012 | 74 | 2012 |
| Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer Y Sanli, C Turkmen, B Bakir, C Iyibozkurt, S Ozel, D Has, E Yilmaz, ... Nuclear medicine communications 33 (5), 509-515, 2012 | 73 | 2012 |
| Safety of fibroblast activation protein–targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04 S Kuyumcu, B Kovan, Y Sanli, F Buyukkaya, DH Simsek, ZG Özkan, ... Clinical nuclear medicine 46 (8), 641-646, 2021 | 66 | 2021 |
| Evidence of prostate-specific membrane antigen expression in hepatocellular carcinoma using 68Ga-PSMA PET/CT S Kuyumcu, D Has-Simsek, R Iliaz, Y Sanli, F Buyukkaya, F Akyuz, ... Clinical nuclear medicine 44 (9), 702-706, 2019 | 50 | 2019 |
| Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET/CT in prostate cancer? DH Simsek, Y Sanli, C Civan, MN Engin, EG Isik, ZG Ozkan, S Kuyumcu Annals of Nuclear Medicine 34, 476-485, 2020 | 33 | 2020 |
| Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results S Kuyumcu, EG Isik, TO Tiryaki, D Has-Simsek, Y Sanli, F Buyukkaya, ... Annals of nuclear medicine 35 (10), 1147-1156, 2021 | 27 | 2021 |
| Fibroblast activation protein–targeted PET imaging of metastatic castration-resistant prostate cancer compared with 68Ga-PSMA and 18F-FDG PET/CT EG Isik, D Has-Simsek, O Sanli, Y Sanli, S Kuyumcu Clinical nuclear medicine 47 (1), e54-e55, 2022 | 25 | 2022 |
| 177Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer Y Sanli, DH Simsek, O Sanli, RM Subramaniam, AT Kendi Biomedicines 9 (4), 430, 2021 | 23 | 2021 |
| Detection of metastases in newly diagnosed prostate cancer by using 68Ga-PSMA PET/CT and its relationship with modified D’Amico risk classification DH Simsek, Y Sanli, MN Engin, S Erdem, O Sanli European journal of nuclear medicine and molecular imaging 48, 1639-1649, 2021 | 21 | 2021 |
| Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? D Has Simsek, S Kuyumcu, S Karadogan, M Oflas, EG Isik, ZG Ozkan, ... Annals of Nuclear Medicine 35, 680-690, 2021 | 20 | 2021 |
| Radionuclide therapy with 177Lu-PSMA in a case of metastatic adenoid cystic carcinoma of the parotid DH Simsek, S Kuyumcu, FY Agaoglu, SN Unal Clinical Nuclear Medicine 44 (9), 764-766, 2019 | 19 | 2019 |
| Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancer DH Simsek, Y Sanli, CB Külle, H Karanlik, B Kiliç, S Kuyumcu, S Önder, ... Nuclear Medicine Communications 38 (8), 694-700, 2017 | 16 | 2017 |
| The role of [68 Ga]Ga-FAPI-04 PET/CT in renal cell carcinoma: a preliminary study C Civan, S Kuyumcu, D Has Simsek, O Sanli, EG Isik, ZG Ozkan, ... European Journal of Nuclear Medicine and Molecular Imaging 51 (3), 852-861, 2024 | 15 | 2024 |
| 225Ac-prostate-specific membrane antigen therapy for castration-resistant prostate cancer: a single-center experience Y Sanli, S Kuyumcu, DH Simsek, F Büyükkaya, C Civan, EG Isik, ... Clinical nuclear medicine 46 (12), 943-951, 2021 | 14 | 2021 |
| Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters: A Single-Center Experience DH Simsek, S Kuyumcu, S Karadogan, ZG Ozkan, EG Isik, M Basaran, ... Clinical Nuclear Medicine, 2022 | 12 | 2022 |
| How accurate is 68Gallium-prostate specific membrane antigen positron emission tomography/computed tomography (68Ga-PSMA PET/CT) on primary lymph node staging before radical … S Erdem, DH Simsek, E Degirmenci, R Aydin, S Bagbudar, Y Ozluk, ... Urologic Oncology: Seminars and Original Investigations 40 (1), 6. e1-6. e9, 2022 | 12 | 2022 |
| Clinical impact of lower-limb imaging in 68Ga-PSMA PET/CT for patients with prostate cancer DH Simsek, Y Sanli, S Kuyumcu, MN Engin, F Buyukkaya, E Demirci Journal of Nuclear Medicine Technology 47 (3), 233-237, 2019 | 12 | 2019 |
| 68Ga-DOTATATE PET–CT imaging in carotid body paragangliomas DH Şimşek, Y Şanlı, S Kuyumcu, B Başaran, A Mudun Annals of Nuclear Medicine 32, 297-301, 2018 | 12 | 2018 |
| An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE B Kovan, ZG Özkan, B Demir, D Tunçman, EG Işik, DH Şimşek, ... Cancer biotherapy & radiopharmaceuticals 37 (1), 17-22, 2022 | 10 | 2022 |
